Skip to main content

 03 4215 0000

Fees

Barwon Health Combined HREC/RGO Fees


In order to meet the increasing costs associated with provision of high quality ethics oversight, and in keeping with the schedule of fees adopted by our Victorian peers, the Barwon Health REGI Unit's fees have been updated, effective 12 February 2020, as outlined in the table of fees below.

*Any other research not covered in the table below is exempt from any review fees.

New Applications

*Fee Payment Form is required as part of the initial application

Commercially Sponsored

Review Fee (inc. GST)

Interventional/Clinical Trial Study

$6,600

All Other Studies

For example: Observational Study/Sub Study/Extension Study/Registry

$3,300

LNR Study

$1,100

Collaborative/Investigator Initiated

Review Fee (inc. GST)

Interventional/Clinical Trial Study with Commercial Support

Funding and/or investigational product provided by pharmaceutical or device company.

$3,300

Interventional/Clinical Trial Study without Commercial Support

Funding obtained from a source other than a pharmaceutical or device company, e.g. Not-for-profit, University, Collaborative Group, Hospital, Research Institution. The fee applies to the Institution deemed to be the custodian of the Protocol and/or the Institution through which a funding application was submitted. Barwon Health and/or Deakin University led trials are exempt from this fee.

$660

All Other Studies with Commercial Support (excluding Interventional/Clinical Trial Studies)

Funding and/or investigational product provided by pharmaceutical or device company.

 

$550

Amendments

Commercially Sponsored 

Review Fee (inc. GST) 

Major Amendment

Includes significant changes that results in an amendment to the Protocol/PICF/IB, change in the primary hypothesis, change to the design of the study, additional outcomes or exposures, use of additional linkages to other databases, addition of study site, etc.

$660

Minor Amendment

Includes changes to the research team, budget, study dates, study documentation, definition to the study population (e.g. numbers recruited, increased age range, etc.), additional analysis (statistical or biological), that are not part of the main findings, etc.

$220

Collaborative/Investigator Initiated

Review Fee (inc. GST) 

Major Amendment with Commercial Support

Funding and/or investigational product provided by pharmaceutical or device company. Includes significant changes that results in an amendment to the Protocol/PICF/IB, change in the primary hypothesis, change to the design of the study, additional outcomes or exposures, use of additional linkages to other databases, addition of study site, etc.

$220

Minor Amendment with Commercial Support

Funding and/or investigational product provided by pharmaceutical or device company. Includes changes to the research team, budget, study dates, definition to the study population (e.g. numbers recruited, increased age range, etc.), additional analysis (statistical or biological), that are not part of the main findings, etc. 

$110

Last Modified: Thursday, 13 February 2020